Agarwal Shefali 4

What Happened

• Shefali Agarwal, a non-employee director of Fate Therapeutics (FATE), received a grant of options covering 87,900 shares on June 12, 2026. The reported acquisition price is $0.00 because this is a derivative award (options), not a cash purchase. The filing does not report a cash value or exercise price in the summary provided.
• This award appears to be routine director compensation rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-12. Form 4 filed: 2026-06-15 (appears timely).
• Transaction code: A (Award/Grant); reported as a derivative instrument (options).
• Shares/options granted: 87,900. Reported acquisition price: $0.00 (derivative award).
• Shares owned following the transaction: Not stated in the provided filing details.
• Footnotes: F1—Grant made under the Issuer's Amended and Restated Non-Employee Director Compensation Policy (annual equity grants to non-employee directors). F2—Options vest and become exercisable on the earlier of June 12, 2027 or the Issuer's 2027 Annual Meeting, subject to continued board service.

Context

• This transaction is an equity compensation award to a director (routine). As a grant of options, it does not involve an immediate cash outlay or sale; value will depend on future vesting and any exercise price (if applicable). Such awards are common for non-employee directors and are generally part of ongoing compensation.